The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." https://rajanjpic374551.blogitright.com/40506592/elite-stakeholder-pharma-the-speculative-wager